CR

Curis

- NASDAQ:CRIS
Last Updated 2019-08-16

LinkedIn Profile

Access Curis historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:cris 73424 Aug 21st, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 21st, 2019 11:59AM Aug 21st, 2019 11:59AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 20th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 20th, 2019 01:12PM Aug 20th, 2019 01:12PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 19th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 18th, 2019 10:17PM Aug 18th, 2019 10:17PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 18th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 17th, 2019 10:17PM Aug 17th, 2019 10:17PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 17th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 16th, 2019 10:17PM Aug 16th, 2019 10:17PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 16th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 16th, 2019 11:17AM Aug 16th, 2019 11:17AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 15th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 15th, 2019 11:52AM Aug 15th, 2019 11:52AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 14th, 2019 12:00AM Curis 2.8K 89.00 Open Biotechnology Aug 14th, 2019 11:46AM Aug 14th, 2019 11:46AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 13th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 12th, 2019 10:18PM Aug 12th, 2019 10:18PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Aug 12th, 2019 12:00AM Curis 2.8K 91.00 Open Biotechnology Aug 12th, 2019 09:36AM Aug 12th, 2019 09:36AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The Company currently has three drug candidates in development:  Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.  CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.  CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Open Drug Development, Oncology, Small molecule, Immunology, biotechnology, Clinical Development Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.